NASDAQ: CVRX · Industrial Applications and Services · 3 alerts · CIK 1235912
Share price
$0.6130Close, Nov 16
Market cap
$17.5M
Shares outstanding
28.49MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CVRx, Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, CVRx reported revenue of $44.3 million, an increase from $40.6 million in the prior year period. Despite the revenue growth, the company reported a net loss of $41.3 million for the first nine months of 2026, consistent with the prior year, as it continues to invest heavily in selling, general, and administrative expenses to support its Barostim product.
CVRx reported third quarter 2026 financial results, with total revenue of $13.8 million, a 6% decrease year-over-year. The decline was primarily attributed to lower sales force productivity and challenges with a major payer, though the company expanded its U.S. active implanting centers to 262.
“While we recognize there is more work ahead, we remain encouraged by the progress we are making on key strategic initiatives, including the expansion of Medicare Advantage coverage and the clinical evidence released at HFSA. With new Medicare Advantage coverage policies, BENEFIT-HF enrolling, and continued focus on commercial execution, we are confident in our ability to bring this therapy to more patients living with heart failure.”
Kevin Hykes, President and Chief Executive Officer of CVRx
CVRx, Inc. appointed John Landry as Chief Financial Officer, effective October 12, 2026, succeeding Jared Oasheim. Mr. Landry's compensation package includes a $500,000 base salary, a 50% target cash incentive, and initial equity awards (75% options, 25% RSUs) representing 0.80% of total common shares outstanding.